Association of gadolinium based magnetic resonance imaging contrast agents and nephrogenic systemic fibrosis.

[1]  M. M. Ahmed,et al.  Nephrogenic Fibrosing Dermopathy , 2008 .

[2]  J. Topf,et al.  Nephrogenic Fibrosing Dermopathy , 2008, TheScientificWorldJournal.

[3]  B. Thiers.  Gadodiamide-Associated Nephrogenic Systemic Fibrosis: Why Radiologists Should Be Concerned , 2008 .

[4]  A. Levy.  Renal Mass Core Biopsy: Accuracy and Impact on Clinical Management , 2008 .

[5]  A. Elster.  Gadolinium-enhanced MR Imaging and Nephrogenic Systemic Fibrosis: Retrospective Study of a Renal Replacement Therapy Cohort , 2008 .

[6]  L. Skov,et al.  Case-control study of gadodiamide-related nephrogenic systemic fibrosis. , 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[7]  E. Kanal,et al.  Response to "Will dialysis prevent the development of nephrogenic systemic fibrosis after gadolinium-based contrast administration?". , 2007, AJR. American journal of roentgenology.

[8]  Michelle G. Goveia,et al.  Evaluating the role of recombinant erythropoietin in nephrogenic systemic fibrosis. , 2007, Journal of the American Academy of Dermatology.

[9]  Sudhir V. Shah,et al.  New insights into nephrogenic systemic fibrosis. , 2007, Journal of the American Society of Nephrology : JASN.

[10]  A. Jardine,et al.  Gadolinium-enhanced MR imaging and nephrogenic systemic fibrosis: retrospective study of a renal replacement therapy cohort. , 2007, Radiology.

[11]  E. Simpson,et al.  Gadolinium Is Not the Only Trigger for Nephrogenic Systemic Fibrosis: Insights From Two Cases and Review of the Recent Literature , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[12]  G. Saab,et al.  Will dialysis prevent the development of nephrogenic systemic fibrosis after gadolinium-based contrast administration? , 2007, AJR. American journal of roentgenology.

[13]  A. Peak,et al.  Risk Factors for Developing Gadolinium-Induced Nephrogenic Systemic Fibrosis , 2007, The Annals of pharmacotherapy.

[14]  Sudhir V. Shah,et al.  Nephrogenic systemic fibrosis, gadolinium, and iron mobilization. , 2007, The New England journal of medicine.

[15]  T. Grobner,et al.  Gadolinium and nephrogenic systemic fibrosis. , 2007, Kidney international.

[16]  John Gosbee,et al.  ACR guidance document for safe MR practices: 2007. , 2007, AJR. American journal of roentgenology.

[17]  A. Djamali,et al.  Nephrogenic systemic fibrosis: risk factors and incidence estimation. , 2007, Radiology.

[18]  S. Cowper,et al.  Nephrogenic systemic fibrosis: a population study examining the relationship of disease development to gadolinium exposure. , 2007, Clinical journal of the American Society of Nephrology : CJASN.

[19]  S. Morcos.  Nephrogenic systemic fibrosis following the administration of extracellular gadolinium based contrast agents: is the stability of the contrast agent molecule an important factor in the pathogenesis of this condition? , 2007, The British journal of radiology.

[20]  Gerald A Kirk,et al.  Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. , 2007, AJR. American journal of roentgenology.

[21]  J. Zic,et al.  Gadolinium deposition in nephrogenic fibrosing dermopathy. , 2007, Journal of the American Academy of Dermatology.

[22]  S. Cowper,et al.  Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. , 2007, Journal of the American Academy of Dermatology.

[23]  M. Port,et al.  Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review , 2006, Fundamental & clinical pharmacology.

[24]  Lone Skov,et al.  Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. , 2006, Journal of the American Society of Nephrology : JASN.

[25]  W. Finn.  The clinical and renal consequences of contrast-induced nephropathy. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[26]  S. Cowper,et al.  Editorials: Nephrogenic Systemic Fibrosis: An Emerging Threat Among Renal Patients , 2006, Seminars in dialysis.

[27]  T. Grobner.  Gadolinium--a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[28]  P. Parfrey,et al.  Preventing Nephropathy Induced by Contrast Medium , 2006 .

[29]  J. Callen,et al.  Nephrogenic fibrosing dermopathy in a patient with acute renal failure never requiring dialysis , 2006, International journal of dermatology.

[30]  P. Parfrey,et al.  Clinical practice. Preventing nephropathy induced by contrast medium. , 2006, The New England journal of medicine.

[31]  G. Israel,et al.  How I do it: evaluating renal masses. , 2005, Radiology.

[32]  G. Stone,et al.  A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. , 2004, Journal of the American College of Cardiology.

[33]  R. Bersin,et al.  Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial. , 2004, JAMA.

[34]  T. Gambichler,et al.  Nephrogenic fibrosing dermopathy , 2004, Clinical and experimental dermatology.

[35]  G. Israel,et al.  Renal imaging for diagnosis and staging of renal cell carcinoma. , 2003, The Urologic clinics of North America.

[36]  W. Ting,et al.  Nephrogenic fibrosing dermopathy with systemic involvement. , 2003, Archives of dermatology.

[37]  R. Swartz,et al.  Nephrogenic fibrosing dermopathy: a novel cutaneous fibrosing disorder in patients with renal failure. , 2003, The American journal of medicine.

[38]  P. Leboit,et al.  Nephrogenic Fibrosing Dermopathy , 2001, The American Journal of dermatopathology.

[39]  T. Kumazaki,et al.  Safety of gadolinium contrast agent in hemodialysis patients. , 2001, Acta radiologica.

[40]  P. Leboit,et al.  Scleromyxoedema-like cutaneous diseases in renal-dialysis patients , 2000, The Lancet.

[41]  J. Debatin,et al.  MR-angiography: the role of contrast agents. , 2000, European journal of radiology.

[42]  M. Knopp,et al.  Off‐label use and reimbursement of contrast media in MR , 1999, Journal of magnetic resonance imaging : JMRI.

[43]  H. Thomsen,et al.  Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. , 1998, Academic radiology.